-
Shop online and enjoy fast delivery to your doorstep!
We deliver everywhere! Anywere!
-
Courier delivery
Our courier will deliver to the specified address
Eye cream with PDRN and peptides that hydrates, firms, and brightens the delicate eye area.
1,750.00৳ Original price was: 1,750.00৳ .1,500.00৳ Current price is: 1,500.00৳ .
We deliver everywhere! Anywere!
Our courier will deliver to the specified address
Payment Methods:
Medicube PDRN Pink Peptide Eye Cream is a nourishing eye treatment formulated with PDRN and peptides to target fine lines, wrinkles, and puffiness around the delicate eye area. Enriched with hydrating and soothing ingredients, it helps firm and lift the skin while reducing dark circles and signs of fatigue. The lightweight yet rich texture absorbs quickly, providing long-lasting moisture and improving skin elasticity for a brighter, youthful-looking eye contour.
| Brand |
Medicube |
|---|
How can you evaluate content without design? No typography, no colors, no layout, no styles, all those things that convey the important signals that go beyond the mere textual, hierarchies of information, weight.
To short sentences, to many headings, images too large for the proposed design, or too small, or they fit in but it looks iffy for reasons the folks in the meeting can’t quite tell right now, but they’re unhappy, somehow.
How can you evaluate content without design? No typography, no colors, no layout, no styles, all those things that convey the important signals that go beyond the mere textual, hierarchies of information, weight.
To short sentences, to many headings, images too large for the proposed design, or too small, or they fit in but it looks iffy for reasons the folks in the meeting can’t quite tell right now, but they’re unhappy, somehow.
How can you evaluate content without design? No typography, no colors, no layout, no styles, all those things that convey the important signals that go beyond the mere textual, hierarchies of information, weight.
Reviews
Clear filtersThere are no reviews yet.